Platelet-Rich Plasma as an Alternative to Xenogeneic Sera in Cell-Based Therapies: A Need for Standardization
Open Access
- 11 June 2022
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (12) , 6552
Abstract
There has been an explosion in scientific interest in using human-platelet-rich plasma (PRP) as a substitute of xenogeneic sera in cell-based therapies. However, there is a need to create standardization in this field. This systematic review is based on literature searches in PubMed and Web of Science databases until June 2021. Forty-one studies completed the selection criteria. The composition of PRP was completely reported in less than 30% of the studies. PRP has been used as PRP-derived supernatant or non-activated PRP. Two ranges could be identified for platelet concentration, the first between 0.14 × 106 and 0.80 × 106 platelets/µL and the second between 1.086 × 106 and 10 × 106 platelets/µL. Several studies have pooled PRP with a pool size varying from four to nine donors. The optimal dose for the PRP or PRP supernatant is 10%. PRP or PRP-derived supernatants a have positive effect on MSC colony number and size, cell proliferation, cell differentiation and genetic stability. The use of leukocyte-depleted PRP has been demonstrated to be a feasible alternative to xenogeneic sera. However, there is a need to improve the description of the PRP preparation methodology as well as its composition. Several items are identified and reported to create guidelines for future research.Keywords
Funding Information
- Eusko Jaurlaritza (KK-2020-00014)
This publication has 109 references indexed in Scilit:
- Functional and differential proteomic analyses to identify platelet derived factors affecting ex vivo expansion of mesenchymal stromal cellsBMC Cell Biology, 2013
- Comparative Effect of Human Platelet Derivatives on Proliferation and Osteogenic Differentiation of Menstrual Blood-Derived Stem CellsMolecular Biotechnology, 2013
- Platelet Lysate as Replacement for Fetal Bovine Serum in Mesenchymal Stromal Cell CulturesTransfusion Medicine and Hemotherapy, 2013
- Molecular basis of anti‐inflammatory action of platelet‐rich plasma on human chondrocytes: Mechanisms of NF‐κB inhibition via HGFJournal of Cellular Physiology, 2010
- Role of Angiopoietin-2 in Regulating Growth and Vascularity of AstrocytomasJournal of Oncology, 2010
- Effect of Solely Applied Platelet‐Rich Plasma on Osseous Regeneration Compared to Bio‐Oss®: A Morphometric and Densitometric Study on Rabbit CalvariaClinical Implant Dentistry and Related Research, 2007
- Beta‐tricalcium phosphate release from brushite cement surfaceJournal of Biomedical Materials Research Part A, 2007
- Platelet-rich plasma improves expansion of human mesenchymal stem cells and retains differentiation capacity andin vivobone formation in calcium phosphate ceramicsPlatelets, 2006
- Autologous platelets as a source of proteins for healing and tissue regenerationThrombosis and Haemostasis, 2004
- Differentiation of MC3T3-E1 Osteoblasts is associated with temporal changes in the expression of IGF-I and IGFBPsBone, 1995